Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Cholestech/Metra Biosystems

This article was originally published in The Gray Sheet

Executive Summary

Cholestech/Metra Biosystems: Sign agreement to develop and market a cassette for the Cholestech L-D-X point-of-care diagnostic system to assess bone resorption. The new cassette will utilize Metra's Pyrilinks-D urine assay, which was cleared by FDA in December 1995 ("The Gray Sheet" Jan. 25, 1996, In Brief). Under the agreement, Cholestech will market the test through its existing distribution channels in the U.S., while the firms will work together to market and distribute the tests internationally. The agreement also provides for the development of cassettes for additional Metra assays that would be added on to the Cholestech system. Metra made "a small equity investment" in Cholestech and will make additional investments "based upon the achievement of certain product development milestones," Cholestech says...

You may also be interested in...

India Rare Disease Policy Proposes Crowdfunding But Patients Feel Let Down

Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.

India’s Hilleman Plans ‘Affordable’ Vaccine Against Group B Strep

India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.

More Surufatinib Cheer For Chi-Med As Second NET Trial Stopped Early

Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts